Issues
-
Cover Image
Cover Image
Benign prostatic hypertrophy (BPH) is a common condition in older men, which can progress to a malignant state over time as cells accumulate tumorigenic features. The cover image depicts immunofluorescence of a mouse prostate harboring telomere DNA damage (red) and smooth muscle hyperplasia (green). Telomere repeat factor 2 (TRF2) deficiency in prostate epithelial cells was found to induce a phenotype that closely resembles human BPH, and mice bearing this lesion eventually developed high-grade prostate tumors with metastatic potential. For more information, see the article on page 1326. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Molecular Cancer Research
Table of Contents
Highlights
Review
Rapid Impact
Cancer “-omics”
Metastasis-Specific Gene Expression in Autochthonous and Allograft Mouse Mammary Tumor Models: Stratification and Identification of Targetable Signatures
Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer
Cancer Genes and Networks
Cell Fate Decisions
Genome Maintenance
Metabolism
Signal Transduction and Functional Imaging
PRAS40 Phosphorylation Correlates with Insulin-Like Growth Factor-1 Receptor-Induced Resistance to Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells
Tumor Microenvironment and Immunobiology
A TGFβ-Dependent Stromal Subset Underlies Immune Checkpoint Inhibitor Efficacy in DNA Mismatch Repair–Deficient/Microsatellite Instability-High Colorectal Cancer
Journal Archive
Molecular Cancer Research
(2002-Present; volumes 1-current)Published monthly since November, 2002.
(ISSN 0008-5472)
Cell Growth & Differentiation
(1990-2002; volumes 1-13)Published monthly 1990- September, 2002.
(ISSN 1044-9523)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.